ARIAD Pharmaceuticals Inc

Most Recent

  • uploads///Eliquis and Sprycel
    Company & Industry Overviews

    Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17

    In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

    By Daniel Collins
  • uploads///Sprycel revenues
    Company & Industry Overviews

    What Sprycel Could Mean for Bristol-Myers Squibb

    In 2016, Bristol-Myer Squibb’s (BMY) Sprycel reported revenues of ~$1.8 billion, which represents a ~13% YoY rise.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Who Is Incyte Collaborating With?

    Incyte’s (INCY) Jakafi is distributed in the United States through a network of specialty pharmacy providers and wholesalers for direct delivery.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Incyte’s Revenue Stream for 2016

    Incyte’s business revenues are reported under three segments: product, royalty, and contract.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why These Collaborations Are Important to Incyte

    Incyte’s (INCY) Jakafi is distributed in the US markets through its network of specialty pharmacy providers and wholesalers for direct delivery to patients or patients’ pharmacies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s in Incyte’s Product Portfolio?

    Incyte’s (INCY) product portfolio includes drugs for oncology as well as other areas.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares to Its Peers

    Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    These Collaborations Could Boost Jakafi Sales

    Incyte’s (INCY) collaborations and developments include its acquisition of Ariad Pharmaceuticals’ (ARIA) European operations in June 2016.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Incyte’s Profitability Improves, Allowing for Revised Guidance

    Incyte (INCY) reported revenues of $246.3 million in 2Q16, an increase of 51% compared to $163 million in 2Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Incyte’s Product Portfolio Includes Potentially Lucrative Drugs

    Incyte’s (INCY) product portfolio includes drugs for oncology as well as non-oncology. It includes targeted therapies as well as immunotherapies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Incyte’s Revenue Stream in 2Q16

    Incyte (INCY) reported revenues of $246.3 million in its 2Q16 results. This converts to a 51% revenue growth in 2Q16 compared to $163 million in 2Q15.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Is Incyte Hurt by Having Only One FDA-Approved Drug?

    Jakafi (ruxolitinib) is Incyte’s only product and the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera, rare types of blood cancer.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Could the Novartis-Xencor Alliance Benefit Novartis?

    As we’ve discussed, Novartis (NVS) is one of the largest pharmaceutical companies by revenue.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    The Details of Incyte’s Agreement with Ariad Pharmaceuticals

    In May 2016, Incyte (INCY) entered into an agreement to acquire the European operations of Ariad Pharmaceuticals (ARIA). It would help Incyte expand its footprint in European markets.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Seattle Genetics’ 1Q16 Earnings: What Are Analysts Expecting?

    Seattle Genetics is set to release its first-quarter 2016 earnings on April 28, 2016. Analysts estimate revenues of around $116 million for 1Q16.

    By Mike Benson
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    IBB Falls as Energy Sector Negatively Influences the Market

    The iShares Nasdaq Biotechnology ETF (IBB) fell by 2.3% and closed at $324.28, 5% lower than its 100-day moving average price of $341.38.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.